Genetic control of dicumarol levels in man
- PMID: 4177776
- PMCID: PMC297437
- DOI: 10.1172/JCI105949
Genetic control of dicumarol levels in man
Abstract
The mean half-life of dicumarol in the plasma of seven sets of identical and seven sets of fraternal twins after a single oral dose of 4 mg/kg was 43.6+/-SD 17.9 hr. Half-lives ranged from 7 to 74 hr in these 28 normal adults not receiving other drugs for 2 wk preceding dicumarol administration. Large differences among unrelated individuals in dicumarol half-life disappeared almost completely in identical twins, but persisted to some extent in most sets of fraternal twins. These results indicate that marked differences among subjects in dicumarol half-life are under genetic rather than environmental control. Reproducibility of values for dicumarol half-life was demonstrated. A direct relationship between the dose and the half-life of dicumarol occurred in unrelated volunteers administered progressively larger doses at 10-day intervals. Dose dependence of the half-life of a drug results in increased variability of half-life and hence in greater risks of toxicity on long-term therapy. Risks of toxicity on the one hand and of failure to anticoagulate adequately on the other can be reduced by determining dicumarol half-life before starting long-term therapy. Half-lives for dicumarol and phenylbutzone tended to be correlated in the 28 twins, but no correlation occurred between dicumarol and antipyrine half-lives.
Similar articles
-
Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man.J Clin Invest. 1969 Dec;48(12):2202-9. doi: 10.1172/JCI106186. J Clin Invest. 1969. PMID: 5389794 Free PMC article.
-
Genetic control of interindividual variations in the inducibility of aryl hydrocarbon hydroxylase in cultured human lymphocytes.Cancer Res. 1976 Dec;36(12):4619-30. Cancer Res. 1976. PMID: 63323
-
Genetic and environmental factors affecting drug response in man.Fed Proc. 1972 Jul-Aug;31(4):1253-69. Fed Proc. 1972. PMID: 4114107 Review. No abstract available.
-
Genetic control of drug levels in man: antipyrine.Science. 1968 Jul 5;161(3836):72-3. doi: 10.1126/science.161.3836.72. Science. 1968. PMID: 5690279
-
Polygenic factors controlling drug response.Med Clin North Am. 1974 Sep;58(5):951-63. doi: 10.1016/s0025-7125(16)32092-2. Med Clin North Am. 1974. PMID: 4138463 Review. No abstract available.
Cited by
-
Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy.Clin Pharmacokinet. 1989 Apr;16(4):238-53. doi: 10.2165/00003088-198916040-00003. Clin Pharmacokinet. 1989. PMID: 2656051 Review.
-
Anticoagulant effect and plasma kinetics of fluorophenindione after a single dose in man.Eur J Clin Pharmacol. 1975 Apr 4;8(3-4):271-5. doi: 10.1007/BF00567127. Eur J Clin Pharmacol. 1975. PMID: 1233224
-
Antipyrine metabolite formation in children in the acute phase of malnutrition and after recovery.Br J Clin Pharmacol. 1980 Oct;10(4):363-8. doi: 10.1111/j.1365-2125.1980.tb01772.x. Br J Clin Pharmacol. 1980. PMID: 7448107 Free PMC article.
-
Pharmacogenomics in early-phase clinical development.Pharmacogenomics. 2013 Jul;14(9):1085-97. doi: 10.2217/pgs.13.81. Pharmacogenomics. 2013. PMID: 23837482 Free PMC article. Review.
-
Oral anticoagulant therapy.Can Med Assoc J. 1971 Nov 20;105(10):1015-6. Can Med Assoc J. 1971. PMID: 4948519 Free PMC article. Clinical Trial. No abstract available.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources